Seung-Jung Park.

For the Ideal Trial Investigators: Trial of Everolimus-Eluting Stents or Bypass Operation for Coronary Disease.. Seung-Jung Park, M.D., Ph.D., Jung-Min Ahn, M.D., Young-Hak Kim, M.D., Duk-Woo Recreation area, M.D., Sung-Cheol Yun, Ph.D., Jong-Adolescent Lee, M.D., Soo-Jin Kang, M.D., Seung-Whan Lee, M.D., Cheol Whan Lee, M.D., Seong-Wook Recreation area, M.D., Suk Jung Choo, M.D., Cheol Hyun Chung, M.D., Jae Won Lee, M.D., David J.Leonard Weather Jr., President-elect of the NMA.. Cecilia Becattini, M.D., Ph.D., Giancarlo Agnelli, M.D., Alessandro Schenone, M.D., Sabine Eichinger, M.D., Eugenio Bucherini, M.D., Mauro Silingardi, M.D., Marina Bianchi, M.D., Marco Moia, M.D., Walter Ageno, M.D., Maria Rita Vandelli, M.D., Elvira Grandone, M.D., and Paolo Prandoni, M.D., Ph.D. For the WARFASA Investigators: Aspirin for Preventing the Recurrence of Venous Thromboembolism The risk of recurrence of venous thromboembolism persists for many years after anticoagulant treatment is certainly withdrawn.1,2 This risk is high among individuals with unprovoked venous thromboembolism particularly,2 about 20 percent of whom have got a recurrence within 2 years after treatment with vitamin K antagonists provides been discontinued.